We found that the CT or CC+CT heterozygotes of the <i>HMGB1</i> rs1045411 polymorphism reduced the risks for lung cancer, while the G/T/C haplotypes of three <i>HMGB1</i> SNPs (rs1360485, rs1045411 and rs2249825) also reduced the risk for lung cancer by almost half (0.486-fold).
We found that the CT or CC+CT heterozygotes of the <i>HMGB1</i> rs1045411 polymorphism reduced the risks for lung cancer, while the G/T/C haplotypes of three <i>HMGB1</i> SNPs (rs1360485, rs1045411 and rs2249825) also reduced the risk for lung cancer by almost half (0.486-fold).
We found that the CT or CC+CT heterozygotes of the <i>HMGB1</i> rs1045411 polymorphism reduced the risks for lung cancer, while the G/T/C haplotypes of three <i>HMGB1</i> SNPs (rs1360485, rs1045411 and rs2249825) also reduced the risk for lung cancer by almost half (0.486-fold).
To investigate the relationship between the high mobility group box protein B1 (HMGB1) single nucleotide polymorphisms (SNPs) rs1412125, rs2249825, and rs1045411 with pneumonia in terms of susceptibility, severity, and inflammatory response.
We found that the CT or CC+CT heterozygotes of the <i>HMGB1</i> rs1045411 polymorphism reduced the risks for lung cancer, while the G/T/C haplotypes of three <i>HMGB1</i> SNPs (rs1360485, rs1045411 and rs2249825) also reduced the risk for lung cancer by almost half (0.486-fold).
We investigated the associations of a single nucleotide polymorphism (SNP; rs1045411) in HMGB1 with various clinical parameters, severity, and prognosis in patients with sepsis, severe sepsis, or septic shock.
We report on the association between 4 SNPs of the <i>HMGB1</i> gene (rs1360485, rs1045411, rs2249825 and rs1412125) and breast cancer susceptibility as well as clinical outcomes in 313 patients with breast cancer and in 217 healthy controls.
We found that the CT or CC+CT heterozygotes of the <i>HMGB1</i> rs1045411 polymorphism reduced the risks for lung cancer, while the G/T/C haplotypes of three <i>HMGB1</i> SNPs (rs1360485, rs1045411 and rs2249825) also reduced the risk for lung cancer by almost half (0.486-fold).
We report on the association between 4 SNPs of the <i>HMGB1</i> gene (rs1360485, rs1045411, rs2249825 and rs1412125) and breast cancer susceptibility as well as clinical outcomes in 313 patients with breast cancer and in 217 healthy controls.
Furthermore, female patients with UCC carrying at least one T allele at rs1045411 were at a lower invasive tumor stage than those with the wild-type allele [odds ratio (OR) = 0.396, 95% CI = 0.169-0.929], similar to nonsmoking patients (OR = 0.607, 95% CI = 0.374-0.985).
The genotypes of HMGB1 rs1412125 (-1615T > C), rs2249825 (3814C > G), and rs1045411 (2262C > T) loci in 328 patients with community-acquired pneumonia (CAP) and 317 healthy subjects were analyzed by Sanger sequencing.
Our results suggest that rs1045411 in HMGB1 is significantly associated with clinical outcomes of Chinese GC patients after surgery, especially in those with aggressive status, which warrants further validation in other ethnic populations.
We found that the CT or CC+CT heterozygotes of the <i>HMGB1</i> rs1045411 polymorphism reduced the risks for lung cancer, while the G/T/C haplotypes of three <i>HMGB1</i> SNPs (rs1360485, rs1045411 and rs2249825) also reduced the risk for lung cancer by almost half (0.486-fold).
In addition, the presence of one G allele in SNPs rs1360485 or rs2249825 was associated with a higher risk of progressing to T2 tumor and distant metastasis amongst HER2-enriched and triple-negative breast cancer (TNBC) tumors compared with luminal A and luminal B tumors.